Results for
"[search-keyword]"
Sponsor content
157 result(s) found, displaying 1 to 10
-
Australian Public Assessment Report (AusPAR)Kyprolis (carfilzomib) has been approved to treat relapsed or refractory multiple myeloma.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for AJEMNYE ustekinumab 45 mg / 0.5 mL solution for subcutaneous injection vial.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for AJEMNYE ustekinumab 90 mg/1.0 ml solution for subcutaneous injection pre-filled syringe.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for AJEMNYE ustekinumab 5 mg / 1.0 mL (130 mg/26 mL) solution for intravenous infusion injection vial.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for AJEMNYE ustekinumab 45 mg / 0.5 mL solution for subcutaneous injection pre-filled syringe.
-
Jul-2024Prescription medicine evaluationActive ingredient: tarlatamab.
-
Cancellation by sponsorRequested by Amgen Australia Pty Ltd
-
Cancellation by sponsorRequested by Amgen Australia Pty Ltd
-
Cancellation by sponsorRequested by Amgen Australia Pty Ltd
-
Cancellation by sponsorRequested by Amgen Australia Pty Ltd